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Abstract
Pulmonary arterial hypertension (PAH) is a fatal disease without a cure. By the 
time patients are diagnosed with PAH, thickening of pulmonary arterial (PA) walls 
and the narrowing of vascular lumen have already developed due to the abnormal 
growth of pulmonary vascular cells, contributing to the elevated pulmonary vascu-
lar resistance and the right ventricle (RV) damage. Therefore, agents that eliminate 
excess pulmonary vascular wall cells have therapeutic potential, and the apoptosis-
based therapy using anti-cancer drugs may be promising for the treatment of PAH. 
However, cell death agents could also exert adverse effects including cardiotoxicity, 
complicating the development of such therapies for PAH patients who already have 
the damaged heart. We tested the concept that programmed cell death-inducing 
anti-cancer drugs may reduce the PA wall thickening using rat models of PAH. We 
found that: (i) The treatment of PAH animals with anthracycline-, proteasome 
inhibitor- or Bcl-2 inhibitor-classes of anti-cancer drugs after the pulmonary vascu-
lar remodeling had already developed resulted in the reversal of PA wall thickening 
and opened up the lumen; (ii) These effects were accompanied by the apoptosis of 
PA wall cells in PAH rats, but not in normal healthy rats, suggesting the anti-cancer 
drugs selectively kill remodeled vascular cells; (iii) The RV affected by PAH was 
not further damaged by anthracyclines or proteasome inhibitors; (iv) While the left 
ventricle (LV) was damaged by these drugs, we identified cardioprotective agents 
that protect the heart against drug-induced cell death without affecting the efficacy 
to reverse the PA remodeling; and (v) docetaxel, not only reversed pulmonary 
vascular remodeling without exerting RV or LV toxicity, but also repaired the RV 
damage caused by PAH. Thus, the inclusion of programmed cell death-inducing 
anti-cancer drugs should be considered for treating PAH patients.
Keywords: anti-cancer drugs, apoptosis, autophagy, heart, programmed cell death, 
pulmonary hypertension, vascular remodeling
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1. Introduction
Pulmonary arterial hypertension (PAH) is a fatal disease that can affect 
both females and males of any age including children. If untreated, increased 
pulmonary vascular resistance results in right heart failure and kills patients 
within several years [1, 2]. Even with the currently available therapeutic drugs 
that are mainly vasodilators, the survival duration of the patients remains unac-
ceptably short [3, 4]. It has been reported that the median survival for patients 
diagnosed with PAH is 2.8 years from the time of diagnosis (3-year survival: 48%) 
if untreated [5, 6]. Even with currently available therapies, only 58–75% of PAH 
patients survive for 3 years [7–10]. PAH is a progressive disease, and by the time 
patients are diagnosed, thickening of pulmonary artery (PA) walls and the nar-
rowing of vascular lumen have already developed due to the abnormal growth of 
pulmonary vascular cells, contributing to the elevated pulmonary vascular resis-
tance and the right ventricle (RV) damage. Therefore, agents that eliminate excess 
pulmonary vascular wall cells have therapeutic potential, and we hypothesize that 
the programmed cell death-based therapy using anti-cancer drugs would help 
treat PAH patients [11]. However, cell death agents could also exert adverse effects 
including cardiotoxicity, complicating the development of such therapies for PAH 
patients with the already damaged heart.
2. Anti-cancer drugs reverse pulmonary vascular remodeling
In our earlier study, we found that an anthracycline anti-cancer drug daunoru-
bicin (DNR) is an effective agent that can cause apoptosis of cultured PA smooth 
muscle cells (PASMCs) [11, 12]. Based on these results, we hypothesized that the 
administration of DNR to rats would result in the reversal of pulmonary vascular 
remodeling. In these experiments, Sprague-Dawley (SD) rats were treated with 
chronic hypoxia (10% oxygen) for 2 weeks to promote the thickening of PA medial 
walls. After the PA wall thickening was developed, rats were injected with DNR and 
maintained in the hypoxia condition for 3 days. As shown in hematoxylin and eosin 
(H&E) stain images of Figure 1A, DNR effectively reduced the PA wall thickness 
[13]. Similarly, in this study, another class of anti-cancer drugs, proteasome inhibitors 
such as MG132 and bortezomib (Figure 1B) also reduced the PA wall thickening in 
the chronic hypoxia model of pulmonary hypertension (PH) in rats [13].
An animal model, in which SD rats are injected with SU5416 and exposed to 
hypoxia promoting severe PAH with pulmonary vascular lesions resembling those 
of humans [14], has become a gold standard to study PAH [15]. The experimental 
design often involves a single subcutaneous injection of SU5416, followed by 
subjecting the animals to chronic hypoxia for 3 weeks. Subsequently, the animals 
are kept in normoxia, and severe PAH and pulmonary vascular remodeling are 
progressively developed. We found that programmed cell death-inducing anti-
cancer drugs reversed pulmonary vascular remodeling in this model of PAH as 
well. Figure 1C shows the results of our experiments, in which another proteasome 
inhibitor, carfilzomib (CFZ) injected 4 times over two weeks after the pulmonary 
vascular remodeling was developed effectively reduced the PA wall thickness in 
PAH rats [16]. Proteasome inhibition-dependent reversal of pulmonary vascular 
remodeling occurred through the reduction of both intimal and medial wall 
thickening, suggesting that both endothelial cells and smooth muscle cells (SMCs) 
can be affected by these anti-cancer drugs [13].
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While anthracyclines such as DNR and proteasome inhibitors are effective 
inducers of apoptosis of PASMCs [11, 13, 16], these agents could exert other biologic 
actions. Thus, we tested the effects of a more ‘pure’ apoptosis inducer, navitoclax 
(ABT-263) that inhibits anti-apoptotic proteins Bcl-2 and Bcl-xL. We found that this 
drug also reversed PA remodeling in SD rats as well as in Fischer rats with PAH pro-
moted by SU5416 + hypoxia (Figure 1D; [17]). The reversal of pulmonary vascular 
remodeling by navitoclax was also recently reported by van der Feen et al. [18] in a 
different experimental model of PAH in rats
These results provided important information, in live experimental animals, 
showing that programmed cell death-inducing anti-cancer drugs are capable of 
reversing pulmonary vascular remodeling in multiple models of PH. While this 
knowledge established a basis for exploring whether causing the death of pulmo-
nary vascular cells clinically benefits PAH patients, it also generated many questions 
that need to be addressed.
Figure 1. 
Effects of programmed cell death-inducing anti-cancer drugs on pulmonary vascular remodeling. (A & B) SD 
rats were treated with chronic hypoxia for 2 weeks to produce pulmonary vascular thickening and injected with 
DNR or bortezomib. Rats were then placed back in the hypoxic environment. Three days after the injection, 
lungs were harvested and H&E staining was performed (Adapted from Ibrahim et al. [13] with permission). 
(C & D) SD rats were subjected to SU5416/hypoxia to promote PAH. After pulmonary vascular remodeling 
was developed, rats were injected with CFZ or navitoclax twice a week for 2 weeks. Lungs were harvested and 
H&E staining was performed (Adapted from Wang et al. [16] and Rybka et al. [17] with permission). Bar 
graphs represent means ± SEM of % PA wall thickness. * denotes that the values are significantly different from 
each other at P < 0.05.
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3.  Susceptibility of normal and diseased cells toward apoptosis-inducing 
anti-cancer drugs
One question is whether both the proliferative synthetic phenotype and the 
differentiated contractile phenotype of PASMCs are killed by these drugs. It is 
preferable that only abnormally grown cells are killed, as it is important to preserve 
contractile SMCs that are needed for the pulmonary circulatory system to function.
The examination of PAs from rats treated with DNR by terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL) staining, which detects 
apoptotic cells, demonstrated that only remodeled PAs of rats with PH exhibited 
apoptotic cells, but not healthy control rats (Figure 2A; [13]). Similar results were 
obtained in the analysis of cleaved caspase-3 as an indication of the occurrence of 
apoptotic cells by Western blotting. As shown in Figure 2B, PAs from rats treated 
with chronic hypoxia to promote PH and subsequently treated with DNR exhibited 
significantly higher levels of cleaved caspase-3 compared to healthy rats injected 
Figure 2. 
Effects of programmed cell death-inducing anti-cancer drugs on apoptosis. (A & B) SD rats were treated with 
chronic hypoxia for 2 weeks to produce pulmonary vascular thickening and injected with DNR. Rats were then 
placed back in the hypoxic environment. Three days after the injection, lungs were harvested and TUNEL 
staining and Western blotting with the cleaved caspase-3 antibody were performed to monitor apoptosis 
(Adapted from Ibrahim et al. [13] with permission). (C & D) SD rats were subjected to SU5416/hypoxia 
to promote PAH. After pulmonary vascular remodeling was developed, rats were injected with CFZ twice a 
week for 2 weeks. Lungs were harvested and TUNEL staining and Western blotting with the cleaved caspase-3 
antibody were performed to monitor apoptosis (Adapted from Wang et al. [16] with permission). Bar graphs 
represent means ± SEM. * denotes that the values are significantly different from each other at P < 0.05.
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with DNR [13]. These results revealed that unwanted abnormally grown pulmonary 
vascular cells can preferentially be killed by this anti-cancer drug.
Results shown in Figure 2C and D demonstrated that this increased suscep-
tibility of pulmonary vascular cells in PH animals can also be seen with another 
anti-cancer drug. CFZ also caused the apoptosis in PAs of rats with PAH induced by 
SU5416/hypoxia, while no apoptosis signals were observed in control healthy rats 
treated with CFZ as monitored by TUNEL assay (Figure 2C) and Western blotting 
using the cleaved caspase-3 antibody (Figure 2D) [16].
We hypothesized that anti-cancer drugs preferentially kill the proliferating 
phenotype of SMCs over differentiated SMCs. Our experiments using cultured 
PASMCs showed that only proliferating SMCs, but not differentiated SMCs, 
were killed by DNR [13]. Figure 3 shows similar experimental results when 
proliferating and differentiated human PASMCs were treated with genistein, 
a naturally occurring isoflavone. DePsipher Mitochondrial Potential assay 
(Trevigen, Gaithersburg, MD, USA) showed that green fluorescent apop-
totic cells were only observed when proliferating PASMCs were treated with 
genistein, while differentiated PASMCs produced by using the Differentiation 
Medium (Cell Applications, Inc., San Diego, CA, USA) were resistant to be killed 
by the same concentration of genistein. These results demonstrate that prolifer-
ating PASMCs are more susceptible to undergo apoptosis compared to differenti-
ated PASMCs, suggesting that apoptosis-inducing drugs eliminated unwanted 
proliferating PASMCs while preserving the contractile phenotypic cells with 
muscle functions.
4. Role of autophagic cell death
One interesting observation we came across in relation to the mechanism of 
PASMC killing by anthracycline- and proteasome inhibitor-classes of anti-cancer 
drug is that, in addition, to apoptosis, another programmed cell death mechanism, 
namely autophagic cell death is also involved. We initially found that autophagy 
of the cells is increased in PAs of PH rats treated with DNR [13]. Similar results 
were observed in cultured proliferating human PASMCs when cells were treated 
with DNR. Further, DNR-induced cell killing was attenuated when an autophagy 
mediator, LC3B, was knocked down [13]. CFZ-induced cell killing was also found to 
involve autophagy, and we further identified the role of tumor protein p53-inducible 
nuclear protein 1 (TP53INP1) in this mechanism [16].
Figure 3. 
Effects of genestein on proliferating and differentiated human PASMC apoptosis. Proliferating human PASMCs 
purchased from Cell Applications grown in Human SMC Growth Medium and differentiated PASMCs 
produced using the Human SMC Differentiation Medium were treated with genistein (50 μM). Apoptotic cells 
were identified by green fluorescence produced using the DePsipher Mitochondrial Potential assay.
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5.  The ability of the remodeled RV to cope with program cell  
death-inducing drugs
Drugs that promote programmed cell death are effective anti-cancer drugs, 
however, they also exert serious potentially life-threatening complications [19]. 
Cardiotoxicity is a major complication that accompanies the use of anti-cancer 
drugs especially anthracyclines. Since PAH patients already have the weakened 
heart, the use of these anti-cancer drugs would be considered to be contraindica-
tions. However, we found that the RV affected by PAH is remarkably resistant 
to drug-induced myocardial cell killing. As we characterized the RV of PAH rats 
injected with DNR to reverse PA remodeling as described above, we found that 
DNR administration to PAH rats did not influence the RV contractility or the 
RV structure [13]. This study also found that DNR did not promote apoptosis of 
cardiomyocytes in hypertrophied RV in rats with PH (Figure 4A; [13]). Similarly, 
CFZ that was found to effectively reverse PA remodeling did not cause apoptosis in 
the RV in SU5416/hypoxia model of PAH in rats (Figure 4B; [16]). These are highly 
significant findings revealing that the RV affected by PAH is resistant to DNR and 
CFZ, drugs that are known induce cardiotoxicity and cardiomyocyte killing in the 
normal heart, providing evidence that the clinical use of these anti-cancer drugs in 
PAH patients may not be contraindications.
By contrast, bortezomib was found to promote apoptosis in both RV and left 
ventricle (LV) of rats with PH induced by monocrotaline [20]. Also, navitoclax 
(ABT-263; an inhibitor of anti-apoptotic proteins, Bcl-2 and Bcl-xL), not only 
Figure 4. 
Effects of programmed cell death-inducing anti-cancer drugs on the RV affected by PAH. (A) SD rats were 
treated with chronic hypoxia for 2 weeks to produce pulmonary vascular thickening and injected with DNR. 
Rats were then placed back in the hypoxic environment. Three days after the injection, RV tissues were 
harvested and Western blotting with the cleaved caspase-3 antibody was performed to monitor apoptosis 
(Adapted from Ibrahim et al. [13] with permission). (B) SD rats were subjected to SU5416/hypoxia to promote 
PAH. After pulmonary vascular remodeling was developed, rats were injected with CFZ twice a week for 2 
weeks. RV tissues were harvested and Western blotting with the cleaved caspase-3 antibody were performed to 
monitor apoptosis (Adapted from Wang et al. [16] with permission). Bar graphs represent means ± SEM. All 
the values were not significantly different from each other at P < 0.05.
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caused apoptosis in the remodeled PA [17], but also promoted apoptosis in RV 
myocytes in PAH rats. Figure 5 shows the transmission electron microscopy images 
of normal SD rat RV myocytes (Figure 5A) and RV myocytes from PAH SD rats 
treated with navitoclax exhibiting signs of apoptosis (Figure 5B). The nuclei PAH 
rats treated with navitoclax underwent the fragmentation with dramatic changes 
in the nuclear chromatin with the segregated heterochromatin that distributed 
preferentially within the nuclear envelope as sharply defined clumped bodies 
(Figure 5B, red arrowheads). The quantification of apoptotic nuclei revealed that 
the most of RV myocytes in PAH rats became apoptotic when treated with navito-
clax (Figure 5C).
These results suggest that, while three classes of anti-cancer drugs have so 
far been found to be effective in reversing PA remodeling, hypertrophied RV 
myocytes are only resistant to DNR and CFZ, while Bcl-2/Bcl-xL inhibition seems 
target downstream of apoptotic pathway thus escapes from the resistance to car-
diomyocyte killing. Whether the RV damaging effects of bortezomib in PAH rats 
[20] is specific to the model induced by monocrotaline that can exert non-specific 
pathophysiologic actions need further investigations, however, the data so far do 
not support the use of bortezomib in the PAH treatment. CFZ that is considered 
to be a safe alternative to bortezomib in cancer therapy [21] and is a more selective 
and irreversible inhibitor of the chymotrypsin-like activity of the 20S proteasome 
[22, 23] could be more promising.
6.  Cardioprotective agents to cope with LV myocyte death by anti-cancer 
drugs
Our laboratory previously found a cell-signaling pathway for the downregula-
tion of Bcl-xL/Bcl-2 that results in the apoptosis of cardiomyocytes [24]. This 
pathway was found as a consequence of our laboratory cloning the promoter region 
of the GATA4 transcription factor that regulates gene transcription of Bcl-xL and 
Bcl-2. We found that CBF/NF-Y binding to the CCAAT box of the Gata4 promoter 
is inhibited by DNR through the activation of p53 in cardiomyocytes [24], but not 
in PASMCs [13]. Thus, we hypothesized that p53 inhibitors would protect the heart 
against cardiotoxicity induced by anti-cancer drugs without affecting the efficacy 
of these drugs to reverse PA remodeling.
Figure 5. 
Navitoclax promotes cardiomyocyte apoptosis in the RV affected by PAH. (A) The normal RV structure of RV 
cardiomyocytes as monitored by transmission electron microscopy. Magnification ×16,000. (B) SD rats were 
subjected to SU5416/hypoxia to promote PAH. After pulmonary vascular remodeling was developed, rats were 
injected with navitoclax twice a week for 2 weeks as described in Rybka et al. [17]. RV tissues were harvested 
and a transmission electron microscope was used to analyze the apoptotic nuclei. Bar graphs represent means 
± SEM. * denotes that the values are significantly different from each other at P < 0.05. Transmission electron 
microscopy studies were performed as described in Shults et al. [32].
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In our study of CFZ as described above, we found that this proteasome inhibitor 
is effective in reversing PA remodeling and that the RV affected by PAH is resistant 
to CFZ toxicity [16]. However, as expected from the earlier cancer studies, CFZ did 
cause the cardiomyocyte apoptosis in the LV of PAH rats (Figure 6A). As a support 
for our hypothesis, this CFZ-induced apoptosis of LV cardiomyocytes was inhibited 
by a p53 inhibitor, pifithrin-α in PAH rats (Figure 6A), while this cardioprotective 
agent did not interfere with CFZ reducing the PA wall thickening (Figure 6B). 
Interestingly, we found that a clinically used cardioprotective drug, dexrazoxane, 
also protected that LV of PAH rats from CFZ toxicity without affecting the reversal 
of PA remodeling. Further investigations are needed to determine whether these 
actions of dexrazoxane involve p53. Nevertheless, these results suggest including 
dexrazoxane or a p53 inhibitor to protect the LV against drug-induced damage while 
treating PAH patients with anti-cancer drugs.
7.  Docetaxel as a fascinating drug that reduces pulmonary vascular wall 
thickening and repairs the damaged right ventricle
Since experiments described above provided results that support the use of 
anti-cancer drugs to reverse pulmonary vascular remodeling, we further searched 
for other drugs that could be useful. In an effort to find effective drugs that prefer-
entially kill proliferating PASMCs, we screened various drugs [25]. We found that 
docetaxel (a taxane class of anti-cancer drugs that stabilizes and inhibits micro-
tubules) effectively killed proliferating human PASMCs, but not differentiated 
human PASMCs in culture [25]. As we tested docetaxel for reversing pulmonary 
vascular remodeling in the SU5416/hypoxia model of PAH, we found that this drug 
indeed was effective in reducing thickened pulmonary vascular walls (Figure 7A). 
Effects were similar to anthracycline-, proteasome inhibitor-, and Bcl-2/Bcl-xL 
Figure 6. 
Dexrazoxane (DEX) and pifithrin-α (PFT-α) protects the LV from CFZ-induced apoptosis without affecting 
the efficacy of CFZ in reversing PA remodeling. (A) PAH rats (SU5416/hypoxia) were divided into 4 groups. 
DEX or PFT-α was injected intraperitoneally along with CFZ, twice a week for two weeks. Rats were then 
sacrificed 3 days after the last injection. LV tissues were homogenized, and subjected to Western blotting for the 
cleaved capase-3 formation. The bar graph represents means ± SEM. * denotes that the values are significantly 
different from each other at P < 0.05. (B) The reduction of remodeled PA thickness induced by CFZ was not 
affected by DEX or PFT-α by analyzing H&E staining. The bar graph represents means ± SEM. * denotes that 
the values are significantly different from the PAH value at P < 0.05. (Adapted from Wang et al. [16] with 
permission).
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inhibitor-classes of drugs. As described above, we found that DNR and CFZ did 
not have adverse effects on the hypertrophied RV in PAH rats while Bcl-2/Bcl-xL 
inhibition resulted in the apoptosis of RV myocytes. Docetaxel also did not exhibit 
adverse effects on the hypertrophied RV in PAH rats. Moreover, this drug repaired 
damaged RV caused by PAH. In SU5416/hypoxia model of PAH, the RV was found 
to have significant cardiac fibrosis as shown in the blue stain of Masson’s trichrome 
staining in Figure 7B. Remarkably, these fibrotic lesions were eliminated by the 
treatment of PAH rats with docetaxel (Figure 7B; [25]).
These results suggest that docetaxel is an effective drug that can reverse pulmo-
nary vascular remodeling and at the same time it can also repair the damaged RV 
caused by PAH at least in SD rats treated with SU5416/hypoxia. Another taxane 
drug, paclitaxel has also been shown to attenuate pulmonary vascular remodeling 
in rodent models of PAH induced by monocrotaline or SU5416/hypoxia [26–30]. 
However, the ability of paclitaxel to repair the RV in PAH animals has not been 
reported. It is interesting to note that paclitaxel has been shown to improve cardiac 
function during ischemia in isolated rat and rabbit hearts [31], reinforcing the idea 
that taxanes have the capacity to promote cardiac repair.
Figure 7. 
Docetaxel reverses pulmonary vascular remodeling and cardiac fibrosis in the RV in PAH rats. SD rats were 
subjected to SU5416/hypoxia to promote PAH. After pulmonary vascular remodeling was developed, rats were 
injected with DTX twice a week for 2 weeks. (A) Lungs were harvested and H&E staining was performed. The 
bar graph represents means ± SEM of % PA wall thickness. * denotes that the values are significantly different 
from each other at P < 0.05. (B) Heart tissues were harvested and Masson’s trichrome staining was performed 
to monitor fibrosis. The bar graph represents means ± SEM of % fiborsis in the RV. * denotes that the values are 
significantly different from the PAH value at P < 0.05. (Adapted from Ibrahim et al. [13] with permission).
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8. Conclusions
We tested the concept that cell death-inducing anti-cancer drugs may reduce 
the PA wall thickening using rat models of PAH. We found that: (1) The treatment 
of PAH rats with anthracycline-, proteasome inhibitor- or Bcl-2/Bcl-xL inhibitor-
classes of drugs after pulmonary vascular remodeling had occurred resulted in the 
reversal of pulmonary vascular remodeling and opened up the lumen; (2) These 
effects were accompanied by the apoptosis of PA wall cells in PAH rats, but these 
drugs did not promote apoptosis in normal healthy rats, suggesting the anti-cancer 
drugs selectively kill remodeled vascular cells; (3) DNR, an anthracycline, and 
CFZ, a proteasome inhibitor, did not adversely affect the hypertrophied RV of PAH 
rats. (4) While the LV was damaged by CFZ, we identified cardioprotective agents 
(dexrazoxane and pifithrin-alpha) that can protect the heart against drug-induced 
cell death without affecting the efficacy of the drugs to reduce PA remodeling;  
(5) Docetaxel, a taxane class of anti-cancer drugs, not only reversed pulmonary 
vascular remodeling without exerting RV or LV toxicity, but also repaired the RV 
damaged caused by PAH. These findings from our laboratory as well as reports by 
other laboratories on the topic of the effects of programmed cell death-inducing 
anti-cancer drugs on remodeled PA and the RV affected by PAH in experimental 
animals are summarized in Table 1.
These results demonstrate that certain anti-cancer drugs effectively and selec-
tively cause programmed cell death of abnormally grown cells in the remodeled 
pulmonary vasculature without adversely affecting the RV in rat models of PAH. 
Thus, the inclusion of programmed cell death-induced anti-cancer drugs may be 
promising for treating PAH patients. Human clinical trials of PAH treatment that 
test the effectiveness of these anti-cancer drugs as mono-therapies or combination 
therapies along with cardioprotective agents described here as well as already avail-
able vasodilators are warranted.
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Reduces remodeled PA Affects remodeled RV
Daunorubicin, DNR (Anthracycline) Yes No effects
Carfilzomib, CFZ (Proteasome inhibitor) Yes No effects
Bortezomib (Proteasome inhibitor) Yes Apoptosis
Navitoclax, ABT-263 (Bcl-2/Bcl-xL inhibitor) Yes Apoptosis
Docetaxel, DTX (Taxane; Microtubule inhibitor) Yes Repairs
Paclitaxel (Taxane; Microtubule inhibitor) Yes Unknown
Table 1. 
Abilities of various anti-cancer drugs to affect PA and RV remodeling.
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